TY - JOUR T1 - Impact of obstructive sleep apnea and intermittent hypoxia on blood rheology – a translational study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00352-2021 SP - 2100352 AU - Waltz, Xavier AU - Beaudin, AndrewE. au -Belaidi，Elise au -Raneri，Jill au -Pépin，Jean -Louis au -Pialoux，Vincent au -Hanly，Hanly，Patrick J. Au -Verges，Samuel Au -Poulin -Poulin，Marc J. Y1-2021/01/01/01/01/01/01/01/01/01/01/01/01/01ur -http：//www.qdcxjkg.com/content/early/2021/04/08/13993003.0033003.00352-2021.ABSTRACT N2-在阻塞性睡眠apnea（OSA）中报告了基本结论性变更，并持续呈阳性空气压力（CPAP）），观察结果可能是通过间歇性缺氧（IH）诱导的氧化应激来解释的。对象研究IH是否通过氧化应激引起了血液学改变。方法使Wistar大鼠暴露于正氧障碍（n = 7）或IH（n = 8）中14天。在三个时间点评估了23名中度至重度OSA患者：基线，随机分配到2周的夜间氧气（n = 13）或没有治疗（n = 10）和CPAP治疗1个月后（n = 17）。此外，在基线和时间匹配后的随访后评估了无OSA对照组（n = 13）。测量我们测量了出血参数[血细胞比容，血液粘度，血浆粘度（仅大鼠），红细胞汇总和不良性（人类）（人类）仅）和氧化还原平衡（SOD，GPX，蛋白质氧化[AOPP]和脂质过氧化[MDA]）。我们还使用氧化剂T叔丁基氢生物氧化物（TBHP）测试了人类参与者中对活性氧（ROS）的红细胞对活性氧（ROS）的敏感性。在大鼠中的反应，IH的血液粘度通过不改变红细胞的血液粘度来增加血液粘度，而不会改变红细胞的血液学特性。IH还减少了SOD活性并增加了AOPP。 In humans, baseline hemorheological properties were similar between patients and controls, and properties were unaltered following oxygen and CPAP, except erythrocyte deformability was reduced following oxygen therapy. Redox balance was comparable between patients and controls. At baseline, TBHP induced a greater reduction of erythrocyte deformability in patients while CPAP reduced TBHP-induced increase in aggregation strength.Conclusion IH and OSA per se do not cause hemorheological alterations despite the presence of oxidative stress or higher sensitivity to ROS, respectively.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Waltz has nothing to disclose.Conflict of interest: Dr. Beaudin reports other from Canadian Institutes of Health Research - Heart and Stroke Foundation of Canada (HSFC), other from Alberta Innovates-Health Solutions (AIHS), from University of Calgary, during the conduct of the study.Conflict of interest: Dr. Beladi has nothing to disclose.Conflict of interest: Dr. Raneri has nothing to disclose.Conflict of interest: Dr. Pépin reports grants and other from Air Liquide Foundation, grants, personal fees and other from Agiradom, grants, personal fees and other from AstraZeneca, grants and personal fees from Fisher and Paykel, grants and personal fees from Mutualia, grants, personal fees and other from Philips, grants, personal fees and other from Resmed, grants and personal fees from Vitalaire, personal fees from Boehringer Ingelheim, personal fees from Jazz Pharmaceutical, personal fees from Night Balance, personal fees from Sefam, outside the submitted work.Conflict of interest: Dr. Pialoux has nothing to disclose.Conflict of interest: Dr. Hanly has nothing to disclose.Conflict of interest: Dr. Verges has nothing to disclose.Conflict of interest: Dr. Poulin has nothing to disclose. ER -